Newspaper logo  
 
 
Local Gov’t Stories, Events

Ref. : Civic Events

Ref. : Arts & Education Events

Ref. : Public Service Notices

Travel
Books, Films, Arts & Education
Letters

Ref. : Letters to the editor

Health Care & Environment

07.28 Insecticide Can Cut Bee Sperm by Nearly 40 Percent, Study Finds

07.28 ExxonMobil Top Sponsor at ALEC's Upcoming Annual Meeting

07.28 Blasting "McCarthy-Like Overreach," State AGs, Climate Groups Won't Comply With GOP Subpoenas

07.27 Worse Than Keystone XL? TransCanada's Terrifying "Plan B" [map]

07.26 EPA ruling on aircraft emissions paves way for new regulations

07.26 How climate change is rapidly taking the planet apart [that "conservative" politicians blithely ignore this crisis is criminal and immoral]

07.26 The green deal is dead: time to revive the great British energy refurb

07.26 China's coal peak hailed as turning point in climate change battle

07.25 The global community is failing to address mental health

07.25 Burning coal for gas in UK seabeds would flame pollution, says report [insane]

07.25 Solar subsidy cuts lead to loss of 12,000 jobs [insane]

07.25 ‘World can’t afford to silence us’: black church leaders address climate change

07.25 'The best solution? Move the Mauritanian capital': water on the rise in Nouakchott

07.25 Pills laced with deadly opioid infiltrating drug market, DEA says

07.25 BLUER SKIES AHEAD FOR OHIO: FIRSTENERGY ANNOUNCES LANDMARK COAL RETIREMENTS [Coal-fired electricity plants decline 45% in 6 years!]

News Media Matters

07.28 Is the French Press Right to stop Printing Pictures, Names of Terrorists?

Daily: FAIR Blog
The Daily Howler

US Politics, Policy & 'Culture'

07.28 Bloomberg's Case Against Trump

07.28 The Next President Will Likely Appoint 4 Supreme Court Justices: Which President Do You Want Picking Them?

07.28 Campaigns End on Election Day. Revolutions Don't.

07.27 Why this is the perfect time to invest in infrastructure, and why it probably won’t happen

07.27 She's With Them–But We've Got Us: A Movement Bigger Than Sanders

07.27 'It's a matter of survival': the black Americans fighting for gun rights

07.26 This Sanders Delegate Unleashing on Hillary Clinton Is Going Absolutely Viral [2:08 video]

07.26 Meet the Latina Bicycle Brigade Fighting Against Gender-Based Violence

07.26 The Unseen Philadelphia

07.26 A Party at War With Itself

07.26 Hillary-Kaine: Back to the Center [Must Read: the bad Hillary is irrepressible and will help Trump enormously, because he's not her]

Justice Matters

07.24 $1 billion alleged Medicare fraud, money laundering scheme leads to Florida arrests [more investigative staff—not staff cuts—could be vastly profitable!]

High Crimes?
Economics, Crony Capitalism

07.28 Hillary’s Choice: Why Tim Kaine Isn’t a ‘Safe’ Pick

07.26 Japan’s “Helicopter Money” Play: Road to Hyperinflation or Cure for Debt Deflation?

07.24 Trump’s tax plan would do little for the average American but a lot for the 1%

07.21 FBI arrests senior HSBC banker accused of rigging multibillion-dollar deal

International

07.28 The only way to defeat Islamic State is to give young Arabs hope

07.27 Welcome to the new age of uncertainty

07.27 Japan to unveil huge $266bn economic stimulus, say reports

07.27 MPs predict surge in immigration amid Brexit uncertainty

07.27 Catalonia tells Spain it will push for secession with or without assent

07.26 Apocalypse Now: A Year of Crises, Shocks and Fears of Terror

07.25 Five clinics in northern Syria hit by regime air raids, say activists

07.25 In Hacking, Russia Accused of Playing in U.S. Politics

We are a non-profit Internet-only newspaper publication founded in 1973. Your donation is essential to our survival.

You can also mail a check to:
Baltimore News Network, Inc.
P.O. Box 42581
Baltimore, MD 21284-2581
Google
This site Web
  Big Pharma Wins Big in Health Care Reform

COMMENTARY:

Big Pharma Wins Big in Health Care Reform

by James Ridgeway
First published in his blog Unsilent Generation yesterday, 22 March 2010
To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

The Republicans look a sour lot this morning, but the pharmaceutical industry, which helps foot the campaign bills of a sizeable chunk of members of both parties, is delighted with the legislation, and with its Democratic friends in the White House and on the Hill.

Members of Congress in both parties generally have lined up behind the insurance and pharmaceutical industries from the get go. So it should come as no surprise that the Democrats, who long ago gave up any pretence of opposing corporate power, found a way to accomodate the pharmaceutical companies on the way to its tepid reform. To a large extent, the “debate” over health care was a show debate, an extended round of Washington smoke and mirrors. The administration early on cut its deal with Big Pharma, and pretty much stuck to it throughout the process.

In fact, the Dems actually made the drugsters look good, celebrating the industry’s generous “concessions” and “discounts” while ensuring that no real threat to Big Pharma’s profits would make their way into the final bill.

The industry’s main goal from the very beginning has been to fend off any government power to negotiate or seriously regulate drug prices–and this they did.

Big Pharma’s second big win was to prevent any measure that would have opened the way for American consumers to buy less expensive drugs abroad, especially from Canada.

At the same time, the supposed give-backs by the drug industry are projected to more than pay for themselves. The much-lauded discounts on brand name drugs for seniors in the Medicare prescription drug program, for example, are good for Big Pharma because they discourage oldsters from switching to generics.

And more insured people simply mean more money coming into the coffers, for Big Pharma as well as for the insurance industry.

Confirmation of the industry analysis came early in the day from the stock market, where drug stocks initially remained level; there certainly was no rush to dump shares, which is what would be expected if the bill actually represented any threat to profits. And by 1 p, EST, CNN Money was reporting a rally in health care stocks.

“I was unable to find anything in there that would cause me to have anxiety if I were a shareholder in a pharmaceutical company,” Ira Loss, a senior health-care analyst at the research firm Washington Analysis, told Dow Jones. According to the ticker story:

Billy Tauzin, who led the industry’s negotiations on health care with lawmakers, said overall drug makers fare well. “While we’re not totally happy,” Tauzin began, “we generally feel like it tracks with our principles.”

Sanofi-Aventis SA (SNY) Chief Executive Christopher Viehbacher said in an interview that the impact of the legislation will be neutral to slightly negative “but better for the industry than if healthcare reform didn’t pass.”

Tauzin, head of the Pharmaceutical Research and Manufacturers of America or PhRMA, and Viehbacher said getting protection for brand-name biologics is among the important provisions for the industry. Drug makers pushed hard to get 12 years of exclusive market protection while the White House and some lawmakers wanted to lower the protection to seven years.

Despite fees and rebates imposed by the legislation, “analysts say drug makers will end up recouping those costs through new customers: The bill would provide insurance coverage to an additional 32 million Americans.” The Dow Jones story continues:

Chalk up another good round for Pharma and Biotech in health care reform,” began a note to clients Friday from Concept Capital, a research firm.Ken Tsuboi, co-manager of the Allianz RCM Wellness Fund, sees the impact of bill, and its $90 billion in concessions over 10 years, as relatively minor in an industry that has annual global sales of about $750 billion, with about $300 billion in the U.S., and margins close to 30%.”I think that it is actually a pretty good deal for Pharma,” Tsuboi said.

The GOP, which purports to be the party of big business, ought to be applauding at least these portions of the health care reform—and perhaps when the cameras go away, some of them will quit bitching and count their blessings. As for the obnoxious Tea Party gang, if they start threatening the real power in this country, which is vested in corporations, they may well find themselves whipped and isolated.


Born in 1936, James Ridgeway has been reporting on politics for more than 45 years. He is currently Senior Washington Correspondent for Mother Jones, and recently wrote a blog on the 2008 presidential election for the Guardian online. He previously served as Washington Correspondent for the Village Voice; wrote for Ramparts and The New Republic; and founded and edited two independent newsletters, Hard Times and The Elements.

Ridgeway is the author of 16 books, including The Five Unanswered Questions About 9/11, It’s All for Sale: The Control of Global Resources, and Blood in the Face: The Ku Klux Klan, Aryan Nations, Nazi Skinheads, and the Rise of a New White Culture. He co-directed a companion film to Blood in the Face and a second documentary film, Feed, and has co-produced web videos for GuardianFilms.

Additional information and samples of James Ridgeway’s work can be found at JamesRidgeway.net and at his newest web site, Solitary Watch.

This article is republished in the Baltimore Chronicle with permission of the author.



Copyright © 2010 The Baltimore News Network. All rights reserved.

Republication or redistribution of Baltimore Chronicle content is expressly prohibited without their prior written consent.

Baltimore News Network, Inc., sponsor of this web site, is a nonprofit organization and does not make political endorsements. The opinions expressed in stories posted on this web site are the authors' own.

This story was published on March 23, 2010.
 



Public Service Ads:
Verifiable Voting in Maryland